Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCI-COG Pediatric MATCH Screening Protocol
NCT03155620Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2017
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 4
01
Overview
Phase 2, open-label trial of larotrectinib, erdafitinib, tazemetostat, samotolisib, selumetinib and 8 more in solid tumor, non-Hodgkin lymphoma (NHL) and histiocytic disorder (13 arms), sponsored by National Cancer Institute. Primary endpoint: Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs up to 2 years. Started Jul 2017; status: active, not recruiting.
02
Drugs
larotrectiniberdafitinibtazemetostatsamotolisibselumetinib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorder
Beyond the preview
Go deeper on NCT03155620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155620.